Anthropic Acquires AI Biotech Startup Coefficient Bio for $400M

The acquisition continues Anthropic's push into healthcare and life sciences.

Apr. 6, 2026 at 3:07pm

Got story updates? Submit your updates here. ›

A highly detailed, glowing 3D macro illustration of a complex network of interconnected circuits and data pathways, representing the advanced AI infrastructure and computational power that powers Anthropic's healthcare and life sciences offerings. Vibrant neon cyan and magenta lights illuminate the intricate hardware, symbolizing the cutting-edge technology at the heart of the Anthropic-Coefficient Bio acquisition.Anthropic's acquisition of Coefficient Bio signals the AI company's growing ambitions in the healthcare and life sciences sectors, where advanced computational power and data-driven insights are transforming drug discovery and biological research.NYC Today

AI company Anthropic has acquired the previously stealth AI biotech startup Coefficient Bio in a $400 million stock deal, according to reports from The Information, Eric Newcomer, and TechCrunch. Coefficient Bio leverages AI to boost efficiency in drug discovery and biological research, and the acquisition is part of Anthropic's broader strategy to expand its presence in the healthcare and life sciences sectors.

Why it matters

Anthropic's acquisition of Coefficient Bio represents the company's continued push into the healthcare and life sciences industries, which it sees as a major strategic priority. The deal comes as Anthropic has been launching new AI tools and capabilities tailored for life sciences applications, from early-stage drug discovery to clinical operations and regulatory affairs.

The details

Coefficient Bio was founded in 2025 and had six employees prior to the acquisition. The startup was led by CEO and co-founder Aris Theologis, who previously held roles at Evozyne and Paragon Biosciences, as well as co-founder and CTO Nathan Frey, who was previously a principal scientist at Biogen. Coefficient Bio leveraged AI to boost efficiency in drug discovery and biological research.

  • Anthropic acquired Coefficient Bio in a $400 million stock deal in April 2026.
  • Anthropic launched its Claude for Life Sciences and Claude for Healthcare offerings in October 2025 and January 2026, respectively.

The players

Anthropic

An AI powerhouse that is continuing to expand its presence in the healthcare and life sciences sectors.

Coefficient Bio

A previously stealth AI biotech startup that was acquired by Anthropic in a $400 million deal. Coefficient Bio leveraged AI to boost efficiency in drug discovery and biological research.

Aris Theologis

The CEO and co-founder of Coefficient Bio, who previously held roles at Evozyne and Paragon Biosciences.

Nathan Frey

The co-founder and CTO of Coefficient Bio, who was previously a principal scientist at Biogen.

Got photos? Submit your photos here. ›

What they’re saying

“For life sciences, it's about making sure that our models have skills spanning everything from early-stage discovery through translation and commercialization, and that they connect to the tools that scientists and life science professionals are using every day.”

— Eric Kauderer-Abrams, Head of Biology and Life Sciences at Anthropic

What’s next

Anthropic and Coefficient Bio have not yet responded to requests for confirmation of the acquisition, and it remains to be seen how the combined capabilities of the two companies will be leveraged in the healthcare and life sciences sectors going forward.

The takeaway

Anthropic's acquisition of Coefficient Bio is the latest in a series of strategic moves by the AI company to expand its presence in the healthcare and life sciences industries, which it views as a major growth opportunity. The deal highlights the increasing importance of AI in driving innovation and efficiency in drug discovery and biological research.